Catalyst defends huge US price hike for rare disease drugCatalyst Pharmaceuticals has defended hiking the price of the rare disease drug Firdapse (amifampridine) from virtually nothing to Share XCatalyst defends huge US price hike for rare disease drughttps://pharmaphorum.com/news/catalyst-defends-huge-us-price-hike-for-rare-disease-drug/
Catalyst sparks price row in US with $300,000 rare disease drugThe controversy over rising drug prices in the US has been reignited after it emerged that the yearly Share XCatalyst sparks price row in US with $300,000 rare disease drughttps://pharmaphorum.com/news/catalyst-sparks-price-row-in-us-with-300000-rare-disease-drug/
Novartis and Lilly CEOs back Trump plans to cut drug pricesCEOs from Novartis and Eli Lilly have backed US government proposals to cut out “middlemen” in the health Share XNovartis and Lilly CEOs back Trump plans to cut drug priceshttps://pharmaphorum.com/news/novartis-and-lilly-ceos-back-trump-plans-to-cut-drug-prices/
Brexit could hinder CAR-T reimbursement in EuropeBrexit and the rise of nationalism in Europe could hinder patients’ access to pricey CAR-T therapies across Europe, Share XBrexit could hinder CAR-T reimbursement in Europehttps://pharmaphorum.com/news/brexit-could-hinder-car-t-reimbursement-in-europe/
Cost concerns with the new NHS pricing schemeA new pricing scheme, which took effect this month, has raised the cap on NHS spending on branded Share XCost concerns with the new NHS pricing schemehttps://pharmaphorum.com/views-analysis-market-access/cost-concerns-with-the-new-nhs-pricing-scheme/
Market access roundup: The US fights back against price hikesDon’t expect the US government’s war on drug pricing to go away any time soon – for once Share XMarket access roundup: The US fights back against price hikeshttps://pharmaphorum.com/views-analysis-market-access/market-access-roundup-the-us-fights-back-against-price-hikes/
Pharma stocks fall after new drug price probe in USUS politicians from the resurgent Democratic party have launched a probe into “unsustainable” drug price rises, prompting their Share XPharma stocks fall after new drug price probe in UShttps://pharmaphorum.com/news/pharma-stocks-fall-after-new-drug-price-probe-in-us/
2018 in review: Governments start taking access seriouslyMarket access has become a key focus for governments across the globe in 2018 – though as ever Share X2018 in review: Governments start taking access seriouslyhttps://pharmaphorum.com/views-analysis-market-access/2018-in-review-governments-start-taking-access-seriously/
Generics firms the ‘biggest cartel in US history’ – reportUS authorities looking into price fixing in the generics industry are now investigating 16 companies and the price Share XGenerics firms the ‘biggest cartel in US history’ – reporthttps://pharmaphorum.com/news/generics-firms-the-biggest-cartel-in-us-history-report/
